Imagion Biosystems (ASX: IBX) is at a pivotal point of its history, about to take its MagSense technology into Phase 2. Abstract: MagSense is a
Earlier this month, our own Bob Proulx, Executive Chairman of Imagion Biosystems, had the opportunity to join Stuart Roberts on Pitt Street Research’s podcast Stocks
Catch Imagion’s CEO, Bob Proulx, chat with 180 Markets CEO, Greg Lowe, about the future of cancer detection and how our MagSense® medical imaging
Tim Boreham has taken another look at Imagion Biosystems in his latest “Dr. Boreham’s Crucible” column on Biotech Daily. In the column, Tim discusses the
“Imagion says it will prioritize development of its Magsense nanoparticle technology as imaging agents for mainstream clinical magnetic resonance imaging (MRI) scanners. Imagion said that
We recently announced that our MagSense® diagnostic technology has the potential to target prostate cancer tumors, making this the second cancer type the technology has
Our Chairman and CEO Bob Proulx was a recent guest at the Fear and Greed podcast, discussing our pursuit of better, more precise imaging solutions to
Bob Proulx sat down with Rozalina Sarkezians, Managing Director & Founder of Health Industry Hub, for a chat about Imagion Biosystem’s work developing our breakthrough
Our CEO, Bob Proulx, connected with the Edison Group during their Global Healthcare Open House to discuss in detail, the nanotechnology behind our bio-imaging MagSense technology
Tim Boreham revisits Imagion Biosystems’ potential in this 5-1/2 page article profiling the company and discussing its recent milestones. Read the article here.